Cartalax
Experimental Peptide
Cartalax is marketed as the short AED peptide, commonly described as Ala-Glu-Asp or Ala-Asp-Glu depending on source. Indexed evidence is limited to cell models and does not establish cartilage repair, joint efficacy, or human safety.
Pharmacokinetic model
A route-level PK model for cartalax is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Experimental Peptide
- Suggested cadence
- once daily
Research behind this entry
-
The influence of peptides on chondrogenic differentiation of human mesenchymal stem cells during replicative aging
AED peptide at 200 ng/mL changed gene expression and protein synthesis in an in-vitro human mesenchymal-stem-cell aging model. It did not test an administered product, animals, joint disease, clinical outcomes, or…
1 published study referenced in the app, each with a plain-language summary.